Compare Enovix Corporation (ENVX) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs GSK plc — how do they compare? Enovix Corporation trades at $4.59 (market cap $1.06B), while GSK plc trades at $50.33 (market cap $102.60B). The key difference: GSK plc is far larger — about 96.8× Enovix Corporation's market cap, and GSK plc pays a 3.57% dividend while Enovix Corporation pays none. Which is the better fit depends on your goals.
| ENVX | GSK | |
|---|---|---|
Market Cap | $1.06B | $102.60B |
Sector | Technology | Health |
52-Week High | $13.19 | $61.18 |
52-Week Low | $3.68 | $38.22 |
Enterprise Value | $1.07B | $123.04B |
Dividend Yield | — | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $4.73, up 1.94% with a bullish technical signal despite negative profitability metrics. The company shows consistent earnings beats but operates at significant losses with a -499.64% net income margin. Recent positive developments include the appointment of a former Apple executive as COO and upcoming Q2 2026 earnings on August 12, 2026.
Analyst consensus remains strongly bullish with a $12.38 price target (162% upside), though execution risks are high given cash burn and negative margins. The stock offers speculative growth potential in advanced battery technology but requires careful risk management due to ongoing operational losses.
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
